Aptargroup, INC 8-K filings

AptarGroup announced its second quarter 2026 financial results, with reported sales surpassing $1 billion for the first time, driven by growth across all segments, particularly in Pharma and Closures.

AptarGroup, Inc. announced the appointment of Aditya J. Gandhi as Vice President, Chief Accounting Officer, effective June 8, 2026, succeeding Daniel Ackerman.

AptarGroup, Inc. announced the final voting results from its Annual Meeting of Stockholders, confirming the election of directors and approval of executive compensation and auditor ratification.

AptarGroup reported flat core sales for Q1 2026 and announced Gael Touya as the incoming CEO effective September 1, 2026.

AptarGroup, Inc. announced the retirement of CEO Stephan Tanda and the appointment of Gael Touya as his successor, effective September 1, 2026, alongside new compensation agreements and retention awards.

AptarGroup, Inc. announced its fourth quarter and annual 2025 results, showing increased sales but decreased net income in Q4, alongside a new $600 million share repurchase authorization.

AptarGroup, Inc. successfully completed an underwritten public offering of $600 million aggregate principal amount of 4.750% Senior Notes due 2031.

AptarGroup reports strong third-quarter 2025 results, driven by significant growth in its Pharma and Closures segments, particularly injectables, while providing a positive outlook for its pharmaceutical pipeline.

AptarGroup, Inc. announced robust second quarter 2025 financial results, with significant increases in sales, net income, and adjusted EBITDA, primarily fueled by strong performance in its Pharma and Closures segments.

AptarGroup's stockholders approved an amendment to the company's 2018 Equity Incentive Plan, increasing the number of shares available for issuance by 1,000,000.

AptarGroup's first quarter 2025 results show a slight decrease in reported sales and net income, but an increase in adjusted EBITDA and margin expansion.

AptarGroup, Inc. announced strong fourth quarter and full year 2024 results, driven by growth in pharma solutions, increased demand for closures technologies, and productivity gains.

AptarGroup's third quarter results show a 19% increase in net income, driven by strong performance in the Pharma and Closures segments.

AptarGroup has announced the retirement of its current CFO, Robert Kuhn, and the appointment of Vanessa Kanu as the new CFO, along with the promotion of Daniel Ackerman to Chief Accounting Officer.

AptarGroup, Inc. announced a 9% increase in net income for the second quarter of 2024, driven by strong performance in its Pharma segment and overall margin expansion.

AptarGroup, Inc. has entered into a second amended and restated credit agreement, securing a new $330 million term loan and modifying its existing $600 million revolving credit facility.

AptarGroup, Inc. amended its certificate of incorporation to include officer exculpation and elected three directors at its 2024 Annual Meeting of Stockholders.

AptarGroup's first quarter of 2024 saw a significant increase in net income and earnings per share, driven by strong performance in the Pharma segment and improved margins in Beauty and Closures.

AptarGroup's fourth quarter and full year 2023 results show strong growth, particularly in their proprietary drug delivery systems and fragrance dispensing technologies.